Oral pharmacological treatment of X-linked dystonia parkinsonism: successes and failures
- PMID: 21244304
- DOI: 10.3109/00207454.2010.544433
Oral pharmacological treatment of X-linked dystonia parkinsonism: successes and failures
Abstract
There is a paucity of published literature on the different oral medications tried for X-linked dystonia parkinsonism (XDP). In practice, most XDP patients are tried or have been tried on medications typically used for patients with generalized dystonia. These drugs include anticholinergic agents, baclofen, clonazepam and other benzodiazepines, tetrabenazine, and clozapine. Although several articles have shown that these classes of drugs are beneficial for patients with generalized dystonia, none have been systematically studied specifically for XDP patients. We are currently conducting the first randomized, placebo-controlled trial on the use of levodopa for the symptomatic treatment of XDP. This article reviews the data on the various dystonia medications that have been used in XDP.
Similar articles
-
The broadening application of chemodenervation in X-linked dystonia-parkinsonism (Part II): an open-label experience with botulinum toxin-A (Dysport®) injections for oromandibular, lingual, and truncal-axial dystonias.Int J Neurosci. 2011;121 Suppl 1:44-56. doi: 10.3109/00207454.2011.558260. Int J Neurosci. 2011. PMID: 21348790 Clinical Trial.
-
The broadening application of chemodenervation in X-linked dystonia-parkinsonism (Part I): muscle afferent block versus botulinum toxin-A in cervical and limb dystonias.Int J Neurosci. 2011;121 Suppl 1:35-43. doi: 10.3109/00207454.2010.544435. Epub 2011 Jan 19. Int J Neurosci. 2011. PMID: 21244305 Review.
-
Phenotypic and molecular analyses of X-linked dystonia-parkinsonism ("lubag") in women.Arch Neurol. 2004 Dec;61(12):1956-9. doi: 10.1001/archneur.61.12.1956. Arch Neurol. 2004. PMID: 15596620
-
First case report of X linked dystonia parkinsonism (XDP) or 'lubag' in Australia.J Clin Neurosci. 2005 Nov;12(8):945-6. doi: 10.1016/j.jocn.2004.10.012. Epub 2005 Oct 20. J Clin Neurosci. 2005. PMID: 16242937
-
The unique phenomenology of sex-linked dystonia parkinsonism (XDP, DYT3, "Lubag").Int J Neurosci. 2011;121 Suppl 1:3-11. doi: 10.3109/00207454.2010.526728. Epub 2010 Nov 3. Int J Neurosci. 2011. PMID: 21047175 Review.
Cited by
-
X-linked dystonia parkinsonism: epidemiology, genetics, clinical features, diagnosis, and treatment.Acta Neurol Belg. 2023 Feb;123(1):45-55. doi: 10.1007/s13760-022-02144-3. Epub 2022 Nov 23. Acta Neurol Belg. 2023. PMID: 36418540 Review.
-
Impact and Challenges of the COVID-19 Pandemic on Patients Requiring Botulinum Toxin A Treatment.J Mov Disord. 2021 Jan;14(1):29-33. doi: 10.14802/jmd.20088. Epub 2021 Jan 12. J Mov Disord. 2021. PMID: 33423433 Free PMC article. No abstract available.
-
X-Linked Dystonia-Parkinsonism: recent advances.Curr Opin Neurol. 2019 Aug;32(4):604-609. doi: 10.1097/WCO.0000000000000708. Curr Opin Neurol. 2019. PMID: 31116117 Free PMC article. Review.
-
Transcranial magnetic resonance-guided focused ultrasound pallidothalamic tractotomy for patients with X-linked dystonia-parkinsonism: a study protocol.BMC Neurol. 2023 Aug 18;23(1):306. doi: 10.1186/s12883-023-03344-x. BMC Neurol. 2023. PMID: 37596524 Free PMC article.
-
Transcranial Magnetic Resonance-Guided Focused Ultrasound in X-Linked Dystonia-Parkinsonism.Life (Basel). 2021 Apr 26;11(5):392. doi: 10.3390/life11050392. Life (Basel). 2021. PMID: 33925939 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources